Luye gains Chinese rights to Hanmi's poziotinib

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) granted Luye Pharma Group Ltd. (HKSE:2186) exclusive rights to develop and commercialize poziotinib ( HM781-36B) in China. The oral pan-HER inhibitor is in Phase II trials to treat HER-2 positive advanced gastric cancer and solid tumors, including HER2-positive breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC). Hanmi will receive up to $20 million in an undisclosed upfront and milestones, plus royalties. ...